Suven Life Sciences wins product patents for SUVN-502 to treat cognitive defects

SUVN-502 patent is valid till June 2023 in all the nine countries

Indian contract services firm Suven Life Sciences Ltd has secured product patents for SUVN-502 in nine regions.

SUVN-502 is Suven Life’s experimental drug for treating cognitive defects associated with Alzheimer’s disease and schizophrenia.

Suven Life Sciences has secured product patents for SUVN-502 in  countries including India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe.

SUVN-502 patent is valid till June 2023 in all these countries.

“Granting of these patents to the SUVN-502 drug is more timely and relevant now that it is ready to enter Phase II proof-of-concept clinical trials during 2010,” Suven Life Chief Executive Venkat Jasti said in a statement.

Suven Life Sciences completed its phase I trials for SUVN-502 in April 2009.

SUVN-502 is a lead compound intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, Schizophrenia.

Suven Life is planning to initiate the clinical Phase-II proof of concept studies for SUVN-502 during 2010.

Suven Life may launch SUVN-502 in later 2013 or in early 2014.

Currently, Suven is looking for a licensing partner to develop SUVN-502 for treating memory and cognition disorders related to Alzheimer’s disease and schizophrenia.

In September, Suven Life Sciences Ltd secured two new US patents for its class of selective 5-HT compounds for the treatment of disorders associated with neurodegenerative diseases like Alzheimer’s disease, Parkinson and schizophrenia .

Suven secured its first US product patent no. US 7,297,711 in December 2007. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven.

In January 2008, Suven announced that the company received its second product Patent number US 7,317,035.  According to the invention ‘035 patent disclosure, the compounds are useful in the treatment of neurodegenarative disorders like Alzheimer’s, Parkinson, Schizophrenia and Huntington’s.

Suven has so far filed 29 product patent applications through PCT covering more than 145 countries, out of which 5 product patents are granted in various countries.

The new patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II, the release stated.

Recently, Suven Life Sciences announced that the company received first milestone payment from Eli Lilly for drug discovery collaboration in central nervous system (CNS) disorder.

Suven achieved with the identification and selection of a 1st Lead compound to be advanced into Lead Optimization Phase of preclinical development.

Suven entered into drug discovery collaboration with Eli Lilly and Company, USA to jointly discover and develop candidates for the treatment of CNS disorders,in 2008. Under the terms of the agreement Lilly will undertake the clinical development of the selected candidate/s and commercialization globally. Lilly will have the full ownership of the candidates developed under this collaboration while Suven receives ongoing research payments and preclinical milestones.

The contract also provides substantial long-term upside for Suven through potential payments for successful milestones achieved during clinical development and royalties on worldwide sales if new drugs are commercialized.

Hyderabad-based Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing therapies through the use of GPCR targets.

Suven has six internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease. Parkinson’s disease and obesity are in addition to developmental candidates in Alzheimer’s disease and schizophrenia.